CZ20013307A3 - Farmaceutické kompozice obsahující komplexy kovů - Google Patents
Farmaceutické kompozice obsahující komplexy kovů Download PDFInfo
- Publication number
- CZ20013307A3 CZ20013307A3 CZ20013307A CZ20013307A CZ20013307A3 CZ 20013307 A3 CZ20013307 A3 CZ 20013307A3 CZ 20013307 A CZ20013307 A CZ 20013307A CZ 20013307 A CZ20013307 A CZ 20013307A CZ 20013307 A3 CZ20013307 A3 CZ 20013307A3
- Authority
- CZ
- Czechia
- Prior art keywords
- bis
- amd
- ruthenium
- methyl
- complex
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
- C07F15/0053—Ruthenium compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12516699P | 1999-03-19 | 1999-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ20013307A3 true CZ20013307A3 (cs) | 2002-05-15 |
Family
ID=22418482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20013307A CZ20013307A3 (cs) | 1999-03-19 | 2000-03-17 | Farmaceutické kompozice obsahující komplexy kovů |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20020049190A1 (enExample) |
| EP (1) | EP1163247A1 (enExample) |
| JP (1) | JP2004500321A (enExample) |
| KR (1) | KR20010112343A (enExample) |
| CN (1) | CN1391577A (enExample) |
| AU (1) | AU3268500A (enExample) |
| BR (1) | BR0011678A (enExample) |
| CA (1) | CA2367282A1 (enExample) |
| CZ (1) | CZ20013307A3 (enExample) |
| HU (1) | HUP0400457A2 (enExample) |
| IL (1) | IL145290A0 (enExample) |
| MX (1) | MXPA01009410A (enExample) |
| NO (1) | NO20014526L (enExample) |
| PL (1) | PL356683A1 (enExample) |
| WO (1) | WO2000056743A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1165576T3 (da) | 1999-04-13 | 2006-03-27 | Anormed Inc | Fremgangsmåde til fremstilling af amin-platin-komplekser |
| JP4227701B2 (ja) * | 1999-05-25 | 2009-02-18 | 中部キレスト株式会社 | ジエチレントリアミン五酢酸ルテニウム二アンモニウム塩またはその水和物およびその製法 |
| US6489638B2 (en) * | 2000-06-23 | 2002-12-03 | Semiconductor Energy Laboratory Co., Ltd. | Light emitting device |
| US6894049B1 (en) | 2000-10-04 | 2005-05-17 | Anormed, Inc. | Platinum complexes as antitumor agents |
| US20020072512A1 (en) * | 2000-12-08 | 2002-06-13 | Metaphore Pharmaceuticals, Inc | Method of preventing and treating HIV-mediated central nervous system damage |
| GB0111872D0 (en) | 2001-05-15 | 2001-07-04 | Northwick Park Inst For Medica | Therapeutic agents and methods |
| EP2319518A1 (en) * | 2002-02-04 | 2011-05-11 | ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. | Use of CO-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
| GB2395432B (en) * | 2002-11-20 | 2005-09-14 | Northwick Park Inst For Medica | Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs |
| GB2395431A (en) * | 2002-11-20 | 2004-05-26 | Northwick Park Inst For Medica | Combination of a metal carbonyl compound and a guanylate cyclase stimulant or stabilizer for the therapeutic delivery of carbon monoxide |
| ES2390457T3 (es) * | 2003-08-04 | 2012-11-13 | Johnson & Johnson Consumer Companies, Inc. | Métodos para el tratamiento de enfermedades dermatológicas |
| ATE537141T1 (de) * | 2004-02-05 | 2011-12-15 | Kyorin Seiyaku Kk | Bicycloesterderivat |
| FR2873037B1 (fr) | 2004-07-13 | 2008-04-11 | Univ Pasteur | Methodes et compositions pour le traitement de cancers |
| CA2631389A1 (en) * | 2005-12-21 | 2007-06-28 | Oxford Biosensors Limited | Redox mediators |
| GB0601394D0 (en) | 2006-01-24 | 2006-03-01 | Hemocorm Ltd | Therapeutic delivery of carbon monoxide |
| US7915427B2 (en) | 2006-03-08 | 2011-03-29 | Kyorin Pharmaceuticals Co., Ltd. | Process for producing aminoacetyl pyrrolidine carbonitrile derivative and intermediate for production thereof |
| CA2655933C (en) | 2006-06-23 | 2014-09-09 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
| WO2008038305A2 (en) * | 2006-09-26 | 2008-04-03 | Jegannathan Srinivas | Therapeutical formulation comprising a thiazolidinedione and a nitric oxide scavenger. |
| JPWO2008114857A1 (ja) | 2007-03-22 | 2010-07-08 | 杏林製薬株式会社 | アミノアセチルピロリジンカルボニトリル誘導体の製造方法 |
| CN104829714A (zh) | 2008-11-03 | 2015-08-12 | 阿莱斯亚生物疗法股份有限公司 | 特异性地阻滞肿瘤抗原的生物活性的抗体 |
| DE102010014412A1 (de) | 2010-04-08 | 2012-04-19 | Friedrich-Schiller-Universität Jena | Verwendung von zweikernigen Eisenkomplexen mit schwefelhaltigen Liganden als pharmakologische Wirkstoffe |
| DE102010014411A1 (de) | 2010-04-08 | 2011-10-13 | Friedrich-Schiller-Universität Jena | Kohlenmonoxid und Eisen freisetzende Moleküle, deren Verwendung und Verfahren zu deren Herstellung |
| CA2893376A1 (en) | 2011-03-31 | 2012-10-04 | Alethia Biotherapeutics Inc. | Antibodies against kidney associated antigen 1 and antigen binding fragemnts thereof |
| PT2699242T (pt) | 2011-04-19 | 2018-01-22 | Alfama Inc | Moléculas de libertação de monóxido de carbono e utilizações das mesmas |
| ES2628634T3 (es) | 2011-07-21 | 2017-08-03 | Alfama, Inc. | Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas |
| AU2013209234B2 (en) | 2012-01-09 | 2017-11-09 | Adc Therapeutics Sa | Method for treating breast cancer |
| DE102012004132A1 (de) | 2012-02-29 | 2013-08-29 | Friedrich-Schiller-Universität Jena | Kohlenstoffmonoxid freisetzende Materialien und deren Verwendung |
| DE102014008537A1 (de) | 2014-06-04 | 2015-12-17 | Friedrich-Schiller-Universität Jena | Wasserlösliche manganbasierte Kohlenstoffmonoxid freisetzende Moleküle, deren Verwendung und Verfahren zu deren Herstellung |
| WO2016065435A2 (en) * | 2014-10-30 | 2016-05-06 | Katholieke Universiteit Leuven | Methods for low temperature fluorine-18 radiolabeling of biomolecules |
| CN113429456B (zh) * | 2021-06-11 | 2022-05-31 | 首都医科大学 | 多肽衍生物钌类络合物及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4721669A (en) * | 1985-01-18 | 1988-01-26 | The Trustees Of Columbia University In The City Of New York | Chemical probes for left-handed DNA and chiral metal complexes as Z-specific anti-tumor agents |
| US5112974A (en) * | 1985-01-18 | 1992-05-12 | The Trustees Of Columbia University In The City Of New York | Mixed ligand complexes and uses thereof as binding agents to DNA |
| GB9317686D0 (en) * | 1993-08-25 | 1993-10-13 | Johnson Matthey Plc | Pharmaceutical compositions |
| SE9703396D0 (sv) * | 1997-09-19 | 1997-09-19 | Lincoln | Binuclear complex |
-
2000
- 2000-03-17 CA CA002367282A patent/CA2367282A1/en not_active Abandoned
- 2000-03-17 WO PCT/CA2000/000294 patent/WO2000056743A1/en not_active Ceased
- 2000-03-17 IL IL14529000A patent/IL145290A0/xx unknown
- 2000-03-17 HU HU0400457A patent/HUP0400457A2/hu unknown
- 2000-03-17 AU AU32685/00A patent/AU3268500A/en not_active Abandoned
- 2000-03-17 CZ CZ20013307A patent/CZ20013307A3/cs unknown
- 2000-03-17 US US09/527,450 patent/US20020049190A1/en not_active Abandoned
- 2000-03-17 MX MXPA01009410A patent/MXPA01009410A/es unknown
- 2000-03-17 KR KR1020017011819A patent/KR20010112343A/ko not_active Withdrawn
- 2000-03-17 EP EP00910468A patent/EP1163247A1/en not_active Withdrawn
- 2000-03-17 PL PL00356683A patent/PL356683A1/xx not_active Application Discontinuation
- 2000-03-17 JP JP2000606604A patent/JP2004500321A/ja not_active Withdrawn
- 2000-03-17 BR BR0011678-5A patent/BR0011678A/pt not_active Application Discontinuation
- 2000-03-17 CN CN00806748A patent/CN1391577A/zh active Pending
-
2001
- 2001-09-18 NO NO20014526A patent/NO20014526L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000056743A1 (en) | 2000-09-28 |
| IL145290A0 (en) | 2002-06-30 |
| HUP0400457A2 (hu) | 2004-05-28 |
| BR0011678A (pt) | 2002-02-26 |
| MXPA01009410A (es) | 2003-06-06 |
| CN1391577A (zh) | 2003-01-15 |
| CA2367282A1 (en) | 2000-09-28 |
| US20020049190A1 (en) | 2002-04-25 |
| AU3268500A (en) | 2000-10-09 |
| NO20014526D0 (no) | 2001-09-18 |
| PL356683A1 (en) | 2004-06-28 |
| JP2004500321A (ja) | 2004-01-08 |
| NO20014526L (no) | 2001-10-16 |
| EP1163247A1 (en) | 2001-12-19 |
| KR20010112343A (ko) | 2001-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20020049190A1 (en) | Pharmaceutical compositions comprising metal complexes | |
| WO2025108479A1 (en) | Compounds for degradation or inhibition of kras mutant proteins and uses thereof | |
| US5824673A (en) | Pharmaceutical compositions comprising metal complexes | |
| US6417182B1 (en) | Pharmaceutical compositions comprising metal complexes | |
| Mészáros et al. | An 8-hydroxyquinoline–proline hybrid with multidrug resistance reversal activity and the solution chemistry of its half-sandwich organometallic Ru and Rh complexes | |
| EP2016085B9 (en) | Transition metal complexes for inhibiting resistance in the treatment of cancer and metastasis | |
| Chen et al. | A ruthenium (II) β-carboline complex induced p53-mediated apoptosis in cancer cells | |
| Shtemenko et al. | Synthesis, characterization, in vivo antitumor properties of the cluster rhenium compound with GABA ligands and its synergism with cisplatin | |
| JP6316479B2 (ja) | カルマンガホジピル、新たな化学実体、および他の混合金属錯体、調製の方法、組成物、および処置の方法 | |
| Wang et al. | Cycloplatinated (II) complex based on isoquinoline alkaloid elicits ferritinophagy-dependent ferroptosis in triple-negative breast cancer cells | |
| Mathuber et al. | Development of a cobalt (III)-based ponatinib prodrug system | |
| Lovison et al. | Cationic carboxylate and thioacetate ruthenium (II) complexes: synthesis and cytotoxic activity against anaplastic thyroid cancer cells | |
| AU2024220523B2 (en) | Tetrazines with improved properties | |
| Sharkawy et al. | A novel benzothiazole-1, 2, 3-triazole-based arene osmium (ii) complex as an effective rhabdomyosarcoma cancer stem cell agent | |
| Mansour et al. | A comprehensive survey of cytotoxic active half-sandwich Ir (III) complexes: structural perspective, and mechanism of action | |
| Lu et al. | Increasing the cytotoxicity of Ru (II) polypyridyl complexes by tuning the electron-donating ability of 1, 10-phenanthroline ligands | |
| Richter et al. | Platinum (ii/iv) complexes with N-substituted carboxylate ethylenediamine/propylenediamine ligands: preparation, characterization and in vitro activity | |
| US20090175775A1 (en) | Metal complexes having vitamin b12 as a ligand | |
| Bartolucci et al. | Five-coordinate platinum (II) complexes containing substituted olefins: synthesis and cytostatic activity | |
| Radanovic et al. | Synthesis and characterization of hexadentate cobalt (III) complexes with novel edta-type ligands. 1. Circular dichroism of a cobalt (III) complex of ethylenediamine-N-acetic-N, N', N'-tri-3-propionic acid | |
| CN114920728B (zh) | 一种甲异靛衍生物及其制备方法与应用 | |
| CN102603812B (zh) | 一种双核铂(ⅱ)–唑来膦酸配合物及其制备和应用 | |
| Romani | Emerging metal-organic anticancer compounds: synthesis and biological activity of novel Ga (III) and Ru (II) complexes | |
| Icsel et al. | Trans-Pd (II) and Pt (II) saccharinate complexes with S, S-diphenylsulfimide: Synthesis, structures, anticancer evaluation and molecular docking | |
| EP4700034A1 (en) | Metal complex compounds, conjugates and conjugatable compounds therefrom as well as uses thereof and processes of producing the same |